Arrowhead Research Corp Trading Up 4.3% Following Analyst Upgrade (ARWR)
Shares of Arrowhead Research Corp (NASDAQ:ARWR) traded up 4.3% during trading on Friday after Jefferies Group raised their price target on the stock from $29.00 to $30.00, Analyst Ratings.Net reports. Jefferies Group currently has a buy rating on the stock. Arrowhead Research Corp traded as high as $14.67 and last traded at $14.49, with a volume of 925,437 shares. The stock had previously closed at $13.89.
A number of other firms have also recently commented on ARWR. Analysts at Zacks reiterated an “outperform” rating on shares of Arrowhead Research Corp in a research note on Tuesday, May 6th. They now have a $18.75 price target on the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Arrowhead Research Corp in a research note on Monday, March 24th. Six research analysts have rated the stock with a buy rating, Arrowhead Research Corp presently has a consensus rating of “Buy” and an average price target of $22.91.
In other Arrowhead Research Corp news, Director Charles Mckenney sold 22,000 shares of the stock on the open market in a transaction dated Monday, June 9th. The stock was sold at an average price of $14.32, for a total transaction of $315,040.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
The stock’s 50-day moving average is $12.40 and its 200-day moving average is $14.47. The company’s market cap is $797.3 million.
Arrowhead Research Corp (NASDAQ:ARWR) last released its earnings data on Tuesday, May 6th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.20) by $0.11. Analysts expect that Arrowhead Research Corp will post $-0.92 EPS for the current fiscal year.
Arrowhead Research Corporation (NASDAQ:ARWR) is a biopharmaceutical company developing targeted RNAi therapeutics.